Compare RTX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | NVO |
|---|---|---|
| Founded | 1934 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.4B | 197.4B |
| IPO Year | 1994 | N/A |
| Metric | RTX | NVO |
|---|---|---|
| Price | $180.75 | $42.11 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 11 |
| Target Price | ★ $204.25 | $51.00 |
| AVG Volume (30 Days) | 4.6M | ★ 11.0M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | 1.57% | ★ 3.19% |
| EPS Growth | ★ 39.72 | N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $80,738,000,000.00 | N/A |
| Revenue This Year | $6.50 | N/A |
| Revenue Next Year | $6.71 | $3.70 |
| P/E Ratio | $118.23 | ★ $13.60 |
| Revenue Growth | ★ 17.15 | N/A |
| 52 Week Low | $135.43 | $35.12 |
| 52 Week High | $214.50 | $81.44 |
| Indicator | RTX | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 44.09 |
| Support Level | $171.22 | $35.49 |
| Resistance Level | $180.70 | $50.30 |
| Average True Range (ATR) | 3.79 | 1.21 |
| MACD | 1.02 | -0.53 |
| Stochastic Oscillator | 77.18 | 19.88 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.